| 1. |
Talati R, Scholle JM, Phung OJ, et al. Effectiveness and safety ofantiepileptic medications in patients with epilepsy. Comparativeeffectiveness review No.40. AHRQ Publication No. 11 (12) -EHC082-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
|
| 2. |
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study ofeffectiveness of carbamazepine, gabapentin, lamotrigine,oxcarbazepine, or topiramate for treatment of partial epilepsy: anunblinded randomised controlled trial. Lancet, 2007, 36(9):1000-1015.
|
| 3. |
Vajda FJE, Lander CM, Hitchcock A, et al. Changing Australianprescribing patterns for antiepileptic drugs in pregnancy and theirpossible consequences. J Clin Neurosci, 2007, 14(2):611-617.
|
| 4. |
Vajda FJE, Horgan D, Hollingworth S, et al. Changing patterns ofantiepileptic drug use in pregnant Australian women. Aust J NZ ObstetGynaec, 2012, 52(10): 49-53.
|
| 5. |
Bobo WV, Davis RL, Toh S, et al. Trends in the use of antiepilepticdrugs among pregnant women in the US, 2001-2007: a medicationexposure in pregnancy risk evaluation study. Paediatr PerinatEpidemiol,2012, 26(5): 578-588.
|
| 6. |
Man SL, Petersen I, Thompson M, et al. Antiepileptic drugs duringpregnancy in primary care: a UK population based study. Plos One, 2012, 7(2): e52339.
|
| 7. |
Tomson T, Battino D. Teratogenic effects of antiepileptic drugs.Lancet Neurol, 2012, 11(3): 803-813.
|
| 8. |
Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine,topiramate and gabapentin. Birth Defects Res A Clin Mol Terato,2012, 94(3): 599-606.
|
| 9. |
Holmes LB, Mittendorf R, Shen A, et al. Fetal effects ofanticonvulsant polytherapies. Arch Neurol, 2011, 68(11): 1275-1281.
|
| 10. |
Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugsand the risk of major birth defects. J Am Med Assoc, 2011, 305(20): 1996-2002.
|
| 11. |
Vajda FJE, Graham J, Hitchcock AA, et al. Is lamotrigine a significanthuman teratogen?Observations from the australian pregnancyregister. Seizure, 2010, 19(2): 558-561.
|
| 12. |
Vajda FJE, Hitchcock A, Graham J, et al. Seizure control inantiepileptic drug-treated pregnancy. Epilepsia, 2008, 49(3): 172-175.
|
| 13. |
Harden C, Hopp J, Ting TY, et al. Management issues for women withepilepsy - focus on pregnancy (an evidence-based review): 1.Obstetrical complications and changes in seizure frequency. Epilepsia, 2009, 50(11): 1229-1236.
|
| 14. |
Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153pregnancies in 59 patients. Epilepsia, 1975, 16(2): 99-110.
|
| 15. |
Schmidt D. The effect of pregnancy on the natural history of epilepsy:review of the literature. In Janz D, Bossi L, Dam M, Helge H, RichensA, Schmidt D (Eds) Epilepsy, pregnancy, and the child. New York,NY: Raven Press, 1982: 3-14.
|
| 16. |
Pirie DAJ, Wattar BHA, Pirie AM, et al. Effect of monitoringstrategies on seizures in pregnant women on lamotrigine: a metaanalysis.Eur J Obstet Gynecol Reprod Biol, 2014, 172(13): 26-31.
|
| 17. |
Reisinger TL, Newman M, Loring DW, et al. Antiepileptic drugclearance and seizure frequency during pregnancy in women withepilepsy. Epilepsy Behav, 2013, 20(2): 13-18.
|
| 18. |
Thomas SV, Syan U, Devi JS. Predictors of seizures during pregnancyin women with epilepsy. Epilepsia, 2011, 53(2): e85-88.
|
| 19. |
Battino D, Tomson T, Bonizzoni E, et al. Seizure control andtreatment changes in pregnancy: observations from the EURAPepilepsy pregnancy registry. Epilepsia, 2013, 54(3): 1621-1627.
|
| 20. |
Sabers A, Petrenaite V. Seizure frequency in pregnant women treatedwith lamotrigine monotherapy. Epilepsia, 2009, 50(10):2163-2166.
|
| 21. |
Mahwinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy.Results from the UK and Ireland epilepsy and pregnancy registers.Neurology, 2013, 80(9): 401-405.
|
| 22. |
Shallcross R, Bromley RL, Irwin B, et al. Child developmentfollowing in utero exposure: levetiracetam vs sodium valproate.Neurology, 2011, 76(9): 383-389.
|
